trichosporonosis
MONDO:0000306
Fungal infections caused by trichosporon that may become systemic especially in an immunocompromised host. Clinical manifestations range from superficial cutaneous infections to systemic lesions in multiple organs.
Research intelligence
Directly mapped studies only · unique clinical trialsCurrent registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.
Medications under investigation
Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.
MONDO disease family
Recruiting studies by city
Trial status
Trial phase
Study start year
Investigated drug interventions
Trichosporonosis
Trichosporonosis is a disease associated with fungi in the genus Trichosporon. It most commonly presents as an infection of hair roots in the skin, causing roughening and loss of hair; this superficial form is also called white piedra. In immunocompromised people, trichosporonosis may progress to an invasive and systemic form which may be life-threatening. In immunocompetent adults, the risk of white piedra progressing to invasive disease is exceptionally low. Treatment of systemic trichosporonosis is often difficult, as Trichosporon species are known to be resistant to most antifungal drugs. Newer triazoles, such as voriconazole, have been reported to have higher efficacy in treatment. A common clinical regimen for the treatment of invasive or severe cutaneous trichosporonosis is a combination of voriconazole, micafungin, and amphotericin B.
Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.Drugs being studied
Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.